Hepatocellular carcinoma to renal cell carcinoma metastasis: a rare phenomenon with diagnostic challenges  by AbdullGaffar, Badr et al.
letter
Hematol Oncol Stem Cell Ther 4(2)     Second Quarter 2011 hemoncstem.edmgr.com 105
Hepatocellular carcinoma 
to renal cell carcinoma 
metastasis: a rare phe-
nomenon with diagnostic 
challenges
To the Editor: The coexistence of 
two or more synchronous or metat
chronous malignancies in the same 
patient is not uncommon.1 Tumort
tottumor metastasis is, however, a 
rarer phenomenon.1,2 Probably, the 
first case reported in the literature 
was by Berent in 1902, in which 
squamous cell carcinoma of the jaw 
metastasized to renal cell carcinot
ma.3 Rabson et al found 50 reported 
cases of cancerttotcancer metastasis 
in 1954.4 Petraki et al found 150 ret
ported cases of tumorttottumor met
tastasis in 2003.1 We report a case of 
hepatocellular carcinoma metastat
sized into renal cell carcinoma.
A 70tyeartold nontlocal woman 
presented with intermittent abdomit
nal pain. Four months prior to current 
presentation the patient was diagnosed 
with hepatocellular carcinoma (HCC) 
in her home country and received one 
cycle of chemotherapy. The patient det
cided to travel abroad to complete her 
treatment in our hospital. Computed 
tomography showed a right hepatic 
lobe mass that measured 7.7 cm with 
chemoembolization material and a 
cirrhotic liver (Figure 1). The left 
kidney showed an upper pole nodt
ule that measured 3.5 cm (Figure 1). 
The right kidney and adrenal glands 
were unremarkable. Alphatfetoprot
tein (AFP) was high (66.3 IU/mL). 
Clinical and radiological differential 
diagnoses included incidental renal 
cell carcinoma or metastatic hepatot
cellular carcinoma of the left kidney 
nodule. The patient was scheduled for 
frozen section of the left renal nodule 
and subsequent segmental resection of 
the hepatic mass.
We received segmental resection 
of the left kidney nodule that grossly 
measured 3.6 cm and showed a yelt
low mass with areas of hemorrhage. 
A frozen section showed histologic 
features of clear cell carcinoma cont
sistent with incidental renal cell 
carcinoma (RCC) of the left kidt
ney. Subsequent permanent sect
tions confirmed the frozen section 
diagnosis of lowtgrade conventional 
renal clear cell carcinoma. However, 
a smaller granular eosinophilic nodt
ule (measuring 2.5 mm) was found 
within the renal cell carcinoma nodt
ule (Figure 2). This nodule showed 
a highly pleomorphic eosinophilic 
neoplasm with focal trabecular and 
pseudoacinar growth pattern lined 
by endothelial cells. High mitotic 
activity with atypical mitotic figures 
was present (Figure 2). Histologic 
differential diagnoses of the smaller 
Figure 1. Computed tomography showed right liver lobe with large mass with 
chemoembolization material. The left kidney showed an upper pole nodule.
Figure 2. Inset showed left renal nodule composed of clear cell carcinoma with 
smaller eosinophilic nodule (hematoxylin and eosin stain, original magnification ×20). 
The interface between the two tumors showed low-grade renal clear cell carcinoma 
and high-grade pleomorphic eosinophilic neoplasm with atypical mitotic figures. 
(Hematoxylin and eosin stain, original magnification ×400).
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eosinophilic nodule included a fot
cus of hightgrade granular renal cell 
carcinoma, metastatic hepatocellular 
carcinoma or adrenal cortical cell 
carcinoma. Immunohistochemistry 
for CD10, HepPart1, AFP and 
melantA was done. The eosinophilic 
neoplastic cells of the small nodule 
were positive for HepPart1 (Figure 
3) and were negative for CD10, AFP 
and melantA. The surrounding renal 
cell carcinoma cells were positive for 
CD10 (Figure 3) and negative for 
the remaining markers. We entert
tained the diagnosis of incidental 
lowtgrade renal cell carcinoma of the 
left kidney with metastatic HCC.
The liver mass was not resected 
because the patient developed severe 
lifetthreatening intraoperative bleedt
ing and received several blood transt
fusions. The patient died two days 
after surgery because of uncontrolled 
hemorrhage. Because of social, ethical 
and religious restrains, postmortem 
examinations are not performed in 
our region, and therefore no autopsy 
study was carried out on the patient.
Tumorttottumor metastasis can 
occur in patients with synchronous 
or metachronous simultaneous 
primaries.1t4 This phenomenon is 
infrequent, but probably more comt
mon than previously reported.1,2 
The receiving host neoplasm could 
be benign or malignant. The most 
common receiving malignancy is 
renal cell carcinoma.1,2,4 Other host 
neoplasms include sarcomas, met
ningiomas, thyroid neoplasms and 
pituitary adenomas.1,2,4 The most 
common donor neoplasm is primary 
lung carcinoma followed by breast, 
prostate and thyroid carcinomas.1,2,4 
Other metastatic donor malignant
cies reported included squamous 
cell carcinoma of the head and neck 
region, melanoma, and colonic and 
gastric carcinomas, but HCC has 
not been previously reported.1t4
The definition of one primary 
malignancy metastasizing to another 
primary neoplasm within the same 
patient should be based on certain 
criteria. Campbell et al5 proposed a 
set of criteria for the diagnosis of tut
mort tottumor metastasis which int
clude: 1) the existence of more than 
Figure 3. HepPar-1 showed positive neoplastic cells in the high-grade eosinophilic 
neoplasm with granular cytoplasmic staining. CD10 showed positive renal cell 
carcinoma cells with membrane staining. (Dako, Glostrup, Denmark, original 
magnification ×400).
one primary tumor in the patient, 2) 
the recipient tumor must be a true 
neoplasm, 3) the donor tumor must 
be a true metastasis (direct contigut
ous spreading or collision tumor is 
not acceptable), and 4) lymphatic 
metastasis should be excluded. The 
reason why RCC was the most comt
mon host malignancy is unclear. 
Several theories have attempted to 
explain why nontmetastasizing early 
renal cell carcinoma is the favorite 
host tumor in cancerttotcancer met
tastasis.1,2 These mechanical and 
biochemical factors include: 1) the 
kidneys are vascular organs with 
abundant blood supply, 2) RCC is 
a very vascular neoplasm, 3) RCC 
provides a lipid and glycogen rich 
environment for tumor growth, 4) 
angiogenic or hormonal secretion 
by RCC cells, and 5) early lowtgrade 
RCC provides an aerobic oxygent
rich metabolic environment suitable 
for tumor growth. These hypotheses 
need validation by more probing 
studies that may shed light into the 
behavior and underlying pathogent
esis of metastasizing cancers.
It is sometimes difficult to dist
tinguish between renal cell carcit
noma and HCC, particularly clear 
cell types. Clues to HCC might 
include the presence of focal trat
becular and pseudoglandular growth 
pattern.6 The presence of bile pigt
ments and Mallory bodies are helpt
ful, but they are not always present 
particularly in high grade HCC.6,7 
Immunohistochemistry with a small 
panel of HepPart1 and CD10 can 
help.6,7 HepPart1 is the most specific 
marker for hepatic differentiation.6,7 
It can be patchy and variable somet
times, but shows characteristic grant
ular cytoplasmic staining.6 HepPart1 
is almost always negative in RCC.6,7 
CD10 is a good marker for RCC, 
but not specific. It can be positive in 
HCC, but usually shows a canalicular 
pattern in the trabecular areas as opt
posed to the brisk membrane staint
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ing in RCC.6,7 AFP is not specific and 
can be negative in HCC.6
In conclusion, tumorttottumor 
metastasis is an infrequent, but not 
a rare event. HCCttotRCC metast
tasis is rare and can be considered 
as one of the rarest cancerttotcant
cer metastasis. Sometimes, it can be 
morphologically difficult to distint
guish between HCC and RCC. This 
could present diagnostic challenges 
to the pathologist, particularly on 
the frozen section. Simple immunot
histochemistry panel of HepPart1 
and CD10 is helpful to distinguish 
between the two neoplasms.
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body in myelodysplastic 
syndrome
To the Editor: CD123 monoclot
nal antibody is an IL3Ra antirecept
tor useful in the diagnosis of hairy 
cell leukemia.1 It is widely used to 
recognize minimal residual disease 
(MRD) in treated acute myeloid 
leukemia (AML). We studied 20 pat
tients with a diagnosis of myelodyst
plastic syndrome (MDS). The most 
prominent clinical sign was leukot
penia with variable lymphocytosis, 
and disease evolution of more than a 
year. Patient ages ranged between 32 
to 81 years, and included 11 women 
and 9 men. Laboratory bone mart
row findings were consistent with 
hypercellular and heteromorphous 
cytology with erythroid dysplasia 
and the presence of PelgertHuett 
anomaly, with increased intermedit
ate forms, immature myeloid series 
and macroplatelets. Serum iron 
and ferritin were measured and 
one marrow iron and biopsy were 
obtained. Flow cytometry monot
clonal antibodies used included 
CD34 + CD123, CD38 + CD123, 
CD34 + CD117, CD34 + CD38, 
CD123, and p53 and Bcl2. These 
monoclonal combinations were 
studied to determine the presence 
of leukemic stem cells (LSC). The 
analysis showed evidence of CD123 
in 12 patients, with more than 20% 
(range, 22%t66%). In the remaint
ing 8 patients, CD123 was less than 
20% (range, 6%t16%). The CD34 
+ CD117 combination findings 
corresponded with 16%t56%s. The 
patient samples were also marked 
with CD38, with a presence of 
39%t82%, indicating cellular activat
tion. When compared with CD34 
+ CD123, the range was 20%t95%. 
Taking into account total positivity, 
all our patients had an increased 
presence of CD123, in addition to 
CD34 and CD117. Eleven (n=11) 
patients presented with alterat
tions in p53, and 14 had the prest
ence BCL2 oncogene. Patients with 
more than 20% CD123 were treated 
with antitmethylation drugs. Our 
conclusions indicate that the use 
of CD123 with other immaturity 
markers corresponds with MDS 
and relates to the presence of LSC. 
The use of this marker may help in 
early identification and treatment of 
cases with higher potential for leut
kemic transformation.  Limited but 
similar findings have been reported 
about the value of CD123, under 
comparable conditions.2 
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